United States ex rel. Nathan v. Takeda Pharm. N. Am., Inc.
134 S. Ct. 1759, 188 L. Ed. 2d 592, 572 U.S. 1033, 82 U.S.L.W. 3566, 2014 WL 1271321, 2014 U.S. LEXIS 2309
Supreme Court of the United States·Decided March 31, 2014·No. No. 12–1349.·Published·Cited by 5 cases
Opinion
Petition for writ of certiorari to the United States Court of Appeals for the Fourth Circuit denied.
Free access — add to your briefcase to read the full text and ask questions with AI
United States ex rel. Nathan v. Takeda Pharm. N. Am., Inc., 134 S. Ct. 1759, 188 L. Ed. 2d 592, 572 U.S. 1033, 82 U.S.L.W. 3566, 2014 WL 1271321, 2014 U.S. LEXIS 2309 (U.S. 2014).
134 S. Ct. 1759 (United States ex rel. Nathan v. Takeda Pharm. N. Am., Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.
Related
United States Ex Rel. Chorches v. American Medical Response, Inc.
865 F.3d 71 (Second Circuit, 2017)
USA ex rel. Todd Heath v. AT&T, Inc.
D.C. Circuit, 2015
United States ex rel. Heath v. AT & T, Inc.
791 F.3d 112 (D.C. Circuit, 2015)
Thomas Foglia v. Renal Ventures Management
754 F.3d 153 (Third Circuit, 2014)